Answers are grounded in this paper and cite their sources.
Real-world study shows weekly RVD regimens have similar effectiveness as twice-weekly regimens in myeloma, suggesting ongoing toxicity challenges.
This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population.
No takes yet. Share an insight, caveat, or question.
Kurniawan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: